FAAH inhibitor

Many FAAH inhibitors were described, but most lack selectivity and bioavailability needed in a drug [1].

[1]

D. Piomelli et al., “Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597),” CNS drug reviews, vol. 12, no. 1, pp. 21–38, 2006, doi: 10.1111/j.1527-3458.2006.00021.x. Available: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2006.00021.x. [Accessed: Nov. 10, 2025]